Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib and Probenecid Drug Interaction Study in Healthy Participants
NCT07840612Phase 1Recruiting
- Sponsor
- Merck KGaA
- Start
- Sep 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of mirdametinib in neurofibromatosis type 1 (NF1) (2 arms), sponsored by Merck KGaA. Primary endpoint: Geometric Mean Ratios of Mirdametinib Pharmacokinetic Plasma Concentration in Presence and Absence of Probenecid. Started Sep 2026; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT07840612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840612.